The Cochrane Library: Cochrane Database of Systematic Reviews

DOI: 10.1002/14651858

Reviews/Protocols listed by Cochrane Review Group


  1. Cochrane Acute Respiratory Infections Group
  2. Cochrane Airways Group
  3. Cochrane Anaesthesia, Critical and Emergency Care Group
  4. Cochrane Back and Neck Group
  5. Cochrane Bone, Joint and Muscle Trauma Group
  6. Cochrane Breast Cancer Group
  7. Cochrane Childhood Cancer Group
  8. Cochrane Colorectal Cancer Group
  9. Cochrane Common Mental Disorders Group
  10. Cochrane Consumers and Communication Group
  11. Cochrane Cystic Fibrosis and Genetic Disorders Group
  12. Cochrane Dementia and Cognitive Improvement Group
  13. Cochrane Developmental, Psychosocial and Learning Problems Group
  14. Cochrane Drugs and Alcohol Group
  15. Cochrane Effective Practice and Organisation of Care Group
  16. Cochrane ENT Group
  17. Cochrane Epilepsy Group
  18. Cochrane Eyes and Vision Group
  19. Cochrane Fertility Regulation Group
  20. Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group
  21. Cochrane Gynaecology and Fertility Group
  22. Cochrane Haematological Malignancies Group
  23. Cochrane Heart Group
  24. Cochrane Hepato-Biliary Group
  25. Cochrane HIV/AIDS Group
  26. Cochrane Hypertension Group
  27. Cochrane IBD Group
  28. Cochrane Incontinence Group
  29. Cochrane Infectious Diseases Group
  30. Cochrane Injuries Group
  31. Cochrane Kidney and Transplant Group
    1. About this group
    2. Reviews
      1. Acupuncture and related interventions for symptoms of chronic kidney diseaseReview
      2. Advance care planning for haemodialysis patientsReview
      3. Aldosterone antagonists for preventing the progression of chronic kidney diseaseReview
      4. Alpha-blockers as medical expulsive therapy for ureteral stonesReview
      5. Altered dietary salt intake for people with chronic kidney diseaseReview
      6. Altered dietary salt intake for preventing and treating diabetic kidney diseaseReview
      7. Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney functionReview
      8. Androgens for the anaemia of chronic kidney disease in adultsReview
      9. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney diseaseReview
      10. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney diseaseReview
      11. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in peritoneal dialysis patientsReview
      12. Antibiotic duration for treating uncomplicated, symptomatic lower urinary tract infections in elderly womenReview
      13. Antibiotic prophylaxis for preventing post solid organ transplant tuberculosisReview
      14. Antibiotics for acute pyelonephritis in childrenReview
      15. Antibiotics for asymptomatic bacteriuriaReview
      16. Antibiotics for preventing recurrent urinary tract infection in non-pregnant womenReview
      17. Antibiotics for treating lower urinary tract infection in childrenReview
      18. Antibody induction therapy for lung transplant recipientsReview
      19. Anticoagulants and antiplatelet agents for preventing central venous haemodialysis catheter malfunction in patients with end-stage kidney diseaseReview
      20. Antidepressants for treating depression in adults with end-stage kidney disease treated with dialysisReview
      21. Antifungal agents for preventing fungal infections in solid organ transplant recipientsReview
      22. Antihypertensive agents for preventing diabetic kidney diseaseReview
      23. Antihypertensive treatment for kidney transplant recipientsReview
      24. Antimicrobial agents for preventing peritonitis in peritoneal dialysis patientsReview
      25. Antimicrobial agents for treating uncomplicated urinary tract infection in womenReview
      26. Antioxidants for chronic kidney diseaseReview
      27. Antiplatelet agents for chronic kidney diseaseReview
      28. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipientsReview
      29. Aspiration and sclerotherapy versus hydrocoelectomy for treating hydrocoelesReview
      30. Astragalus (a traditional Chinese medicine) for treating chronic kidney diseaseReview
      31. Atrial natriuretic peptide for preventing and treating acute kidney injuryReview
      32. Belatacept for kidney transplant recipientsReview
      33. Bicarbonate- versus lactate-buffered solutions for acute continuous haemodiafiltration or haemofiltrationReview
      34. Bicarbonate versus lactate solutions for acute peritoneal dialysisReview
      35. Biocompatible dialysis fluids for peritoneal dialysisReview
      36. Biocompatible hemodialysis membranes for acute renal failureReview
      37. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patientsReview
      38. Calcium channel blockers for preventing acute tubular necrosis in kidney transplant recipientsReview
      39. Cardiac testing for coronary artery disease in potential kidney transplant recipientsReviewDiagnostic
      40. Catheter type, placement and insertion techniques for preventing peritonitis in peritoneal dialysis patientsReview
      41. Cellulose, modified cellulose and synthetic membranes in the haemodialysis of patients with end-stage renal diseaseReview
      42. Chinese herbal medicine for treating recurrent urinary tract infections in womenReview
      43. Chinese herbal medicine Huangqi type formulations for nephrotic syndromeReview
      44. Citrate salts for preventing and treating calcium containing kidney stones in adultsReview
      45. Clinical symptoms, signs and tests for identification of impending and current water-loss dehydration in older peopleReviewDiagnostic
      46. Continuous ambulatory peritoneal dialysis (CAPD) versus hospital or home haemodialysis for end-stage renal disease in adultsReview
      47. Continuous ambulatory peritoneal dialysis versus automated peritoneal dialysis for end-stage renal diseaseReview
      48. Continuous renal replacement therapy (CRRT) for rhabdomyolysisReview
      49. Cordyceps sinensis (a traditional Chinese medicine) for kidney transplant recipientsReview
      50. Cordyceps sinensis (a traditional Chinese medicine) for treating chronic kidney diseaseReview
      51. Correction of chronic metabolic acidosis for chronic kidney disease patientsReview
      52. Corticosteroid therapy for nephrotic syndrome in childrenReview
      53. Cranberries for preventing urinary tract infectionsReview
      54. Cranberries for treating urinary tract infectionsReview
      55. Cytomegalovirus prophylaxis with antiviral agents for solid organ transplantationReviewWithdrawn
      56. Darbepoetin for the anaemia of chronic kidney diseaseReview
      57. Dietary interventions for mineral and bone disorder in people with chronic kidney diseaseReview
      58. Dietary interventions for preventing complications in idiopathic hypercalciuriaReview
      59. Dimercaptosuccinic acid scan or ultrasound in screening for vesicoureteral reflux among children with urinary tract infectionsReviewDiagnostic
      60. Double bag or Y-set versus standard transfer systems for continuous ambulatory peritoneal dialysis in end-stage kidney diseaseReview
      61. Duration of antibacterial treatment for uncomplicated urinary tract infection in womenReview
      62. Early referral to specialist nephrology services for preventing the progression to end-stage kidney diseaseReview
      63. Early versus delayed erythropoietin for the anaemia of end-stage kidney diseaseReview
      64. Education programmes for people with diabetic kidney diseaseReview
      65. Effects of nonsteroidal anti-inflammatory drugs on postoperative renal function in adults with normal renal functionReview
      66. Emergency interventions for hyperkalaemiaReview
      67. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysisReview
      68. Exercise training for adults with chronic kidney diseaseReview
      69. Extracorporeal shock wave lithotripsy (ESWL) versus percutaneous nephrolithotomy (PCNL) or retrograde intrarenal surgery (RIRS) for kidney stonesReview
      70. Extracorporeal shock wave lithotripsy (ESWL) versus ureteroscopic management for ureteric calculiReview
      71. Fish oil for kidney transplant recipientsReview
      72. Fluids and diuretics for acute ureteric colicReview
      73. Frequency of administration of erythropoiesis-stimulating agents for the anaemia of end-stage kidney disease in dialysis patientsReview
      74. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipientsReviewNew
      75. Growth hormone for children with chronic kidney diseaseReview
      76. Haemodiafiltration, haemofiltration and haemodialysis for end-stage kidney diseaseReview
      77. Haemoglobin and haematocrit targets for the anaemia of chronic kidney diseaseReview
      78. Heparin and related substances for preventing diabetic kidney diseaseReview
      79. High-flux versus low-flux membranes for end-stage kidney diseaseReview
      80. HMG CoA reductase inhibitors (statins) for dialysis patientsReview
      81. HMG CoA reductase inhibitors (statins) for kidney transplant recipientsReview
      82. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysisReview
      83. HMG CoA reductase inhibitors (statins) for preventing acute kidney injury after surgical procedures requiring cardiac bypassReview
      84. Home versus in-centre haemodialysis for end-stage kidney diseaseReview
      85. Human albumin for intradialytic hypotension in haemodialysis patientsReview
      86. Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney functionReview
      87. Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipientsReview
      88. Immunosuppressive agents for treating IgA nephropathyReview
      89. Immunosuppressive treatment for focal segmental glomerulosclerosis in adultsReview
      90. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndromeReview
      91. Intensity of continuous renal replacement therapy for acute kidney injuryReview
      92. Interleukin 2 receptor antagonists for kidney transplant recipientsReview
      93. Intermittent versus continuous renal replacement therapy for acute renal failure in adultsReview
      94. Interventions for chronic kidney disease-associated restless legs syndromeReview
      95. Interventions for covert bacteriuria in childrenReview
      96. Interventions for dialysis patients with hepatitis C virus (HCV) infectionReview
      97. Interventions for erythropoietin-resistant anaemia in dialysis patientsReview
      98. Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpuraReview
      99. Interventions for HIV-associated nephropathyReview
      100. Interventions for idiopathic steroid-resistant nephrotic syndrome in childrenReview
      101. Interventions for lowering plasma homocysteine levels in dialysis patientsReview
      102. Interventions for lowering plasma homocysteine levels in kidney transplant recipientsReview
      103. Interventions for metabolic bone disease in children with chronic kidney diseaseReview
      104. Interventions for minimal change disease in adults with nephrotic syndromeReview
      105. Interventions for preventing and treating kidney disease in Henoch-Schönlein Purpura (HSP)Review
      106. Interventions for preventing bone disease in kidney transplant recipientsReview
      107. Interventions for preventing infection in nephrotic syndromeReview
      108. Interventions for preventing infectious complications in haemodialysis patients with central venous cathetersReview
      109. Interventions for preventing the progression of autosomal dominant polycystic kidney diseaseReview
      110. Interventions for primary vesicoureteric refluxReview
      111. Interventions for renal vasculitis in adultsReview
      112. Interventions for treating sexual dysfunction in patients with chronic kidney diseaseReview
      113. Ischaemic preconditioning for the reduction of renal ischaemia reperfusion injuryReviewNew
      114. Isolation as a strategy for controlling the transmission of hepatitis C virus (HCV) infection in haemodialysis unitsReview
      115. Laparoendoscopic single-site donor nephrectomy (LESS-DN) versus standard laparoscopic donor nephrectomyReview
      116. Laparoscopic versus open nephrectomy for live kidney donorsReview
      117. Lipid-lowering agents for nephrotic syndromeReview
      118. Long-term antibiotics for preventing recurrent urinary tract infection in childrenReview
      119. Loop diuretics for patients receiving blood transfusionsReview
      120. Low protein diets for chronic kidney disease in non diabetic adultsReview
      121. Methenamine hippurate for preventing urinary tract infectionsReview
      122. Modes of administration of antibiotics for symptomatic severe urinary tract infectionsReview
      123. Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipientsReview
      124. Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in childrenReview
      125. Non-immunosuppressive treatment for IgA nephropathyReview
      126. Nonsteroidal anti-inflammatory drugs (NSAIDs) and non-opioids for acute renal colicReview
      127. Nonsteroidal anti-inflammatory drugs (NSAIDS) versus opioids for acute renal colicReview
      128. Normal saline versus lower-chloride solutions for kidney transplantationReview
      129. Nutritional support for acute kidney injuryReview
      130. Oestrogens for preventing recurrent urinary tract infection in postmenopausal womenReview
      131. Oral adsorbents for preventing or delaying the progression of chronic kidney diseaseReview
      132. Parenteral versus oral iron therapy for adults and children with chronic kidney diseaseReview
      133. Pentoxifylline for diabetic kidney diseaseReview
      134. Percussion, diuresis, and inversion therapy for the passage of lower pole kidney stones following shock wave lithotripsyReview
      135. Pharmacological interventions for preventing complications in idiopathic hypercalciuriaReview
      136. Pharmacological interventions for the acute management of hyperkalaemia in adultsReview
      137. Phosphate binders for preventing and treating bone disease in chronic kidney disease patientsReview
      138. Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipientsReview
      139. Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipientsReview
      140. Pre-emptive correction for haemodialysis arteriovenous access stenosisReview
      141. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipientsReview
      142. Preoperative vascular access evaluation for haemodialysis patientsReview
      143. Probiotics for preventing urinary tract infections in adults and childrenReview
      144. Procalcitonin, C-reactive protein, and erythrocyte sedimentation rate for the diagnosis of acute pyelonephritis in childrenReviewDiagnostic
      145. Prostaglandin E1 for preventing the progression of diabetic kidney diseaseReview
      146. Protein restriction for children with chronic kidney diseaseReview
      147. Psychosocial interventions for depression in dialysis patientsReview
      148. Quinolones for uncomplicated acute cystitis in womenReview
      149. Recombinant human erythropoietin versus placebo or no treatment for the anaemia of chronic kidney disease in people not requiring dialysisReview
      150. Rheum officinale (a traditional Chinese medicine) for chronic kidney diseaseReview
      151. Routine intraoperative ureteric stenting for kidney transplant recipientsReview
      152. Screening with urinary dipsticks for reducing morbidity and mortalityReview
      153. Short-acting erythropoiesis-stimulating agents for anaemia in predialysis patientsReview
      154. Short versus standard duration oral antibiotic therapy for acute urinary tract infection in childrenReview
      155. Sodium bicarbonate supplements for treating acute kidney injuryReview
      156. Steroid avoidance or withdrawal for kidney transplant recipientsReview
      157. Steroid avoidance or withdrawal for pancreas and pancreas with kidney transplant recipientsReview
      158. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipientsReview
      159. Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipientsReview
      160. Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipientsReview
      161. Teicoplanin versus vancomycin for proven or suspected infectionReview
      162. Thyroid hormones for acute kidney injuryReview
      163. Tidal versus other forms of peritoneal dialysis for acute kidney injuryReview
      164. Topical corticosteroids for treating phimosis in boysReview
      165. Treatment for lupus nephritisReview
      166. Treatment for peritoneal dialysis-associated peritonitisReview
      167. Tripterygium wilfordii Hook F (a traditional Chinese medicine) for primary nephrotic syndromeReview
      168. Ultrasound use for the placement of haemodialysis cathetersReview
      169. Urinary alkalisation for symptomatic uncomplicated urinary tract infection in womenReview
      170. Vitamin B and its derivatives for diabetic kidney diseaseReview
      171. Vitamin D compounds for people with chronic kidney disease not requiring dialysisReview
      172. Vitamin D compounds for people with chronic kidney disease requiring dialysisReview
      173. Water for preventing urinary stonesReview
    3. Protocols
      1. Acetylcysteine for preventing contrast-induced nephropathyProtocolWithdrawn
      2. Adjunctive medical expulsive therapy for kidney and ureteral stone fragments following shock wave lithotripsyProtocol
      3. Analgesia for patients undergoing shockwave lithotripsy for urinary stonesProtocolWithdrawn
      4. Antibiotics for asymptomatic bacteriuria in kidney transplant recipientsProtocol
      5. Antibody immunosuppression for pancreas and kidney-pancreas transplant recipientsProtocol
      6. Anticoagulation for people receiving long-term haemodialysisProtocol
      7. Antihypertensive agents for children with chronic kidney diseaseProtocolWithdrawn
      8. Antimicrobial lock solutions for preventing catheter-related infections in haemodialysisProtocol
      9. Calcineurin inhibitor withdrawal or tapering for kidney transplant recipientsProtocol
      10. Calcium channel blockers as medical expulsive therapy for ureteric stonesProtocol
      11. Calcium channel blockers for people with chronic kidney disease requiring dialysisProtocol
      12. Catheter insertion techniques for improving catheter function and clinical outcomes in peritoneal dialysis patientsProtocol
      13. Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney diseaseProtocol
      14. Dialysate sodium levels for chronic haemodialysisProtocol
      15. Dialysate temperature reduction for intradialytic hypotension for people with chronic kidney disease requiring haemodialysisProtocolNew
      16. Dietary patterns for adults with chronic kidney diseaseProtocol
      17. Direct renin inhibitors for preventing the progression of diabetic kidney diseaseProtocol
      18. Diuretics for people with chronic kidney diseaseProtocol
      19. Donor organ preservation techniques for kidney transplantationProtocol
      20. Early versus late ureteric stent removal after kidney transplantationProtocol
      21. Effects of peri-operative nonsteroidal anti-inflammatory drugs on postoperative kidney function for adults with normal kidney functionProtocol
      22. eHealth interventions for people with chronic kidney diseaseProtocol
      23. Exercise training for adult lung transplant recipientsProtocol
      24. Fenoldopam for preventing and treating acute kidney injuryProtocolWithdrawn
      25. Glucose targets for preventing diabetic kidney disease and its progressionProtocol
      26. Graft nephrectomy for people with a failed kidney transplantProtocol
      27. Haemodialysis duration, frequency and intensity for end-stage kidney diseaseProtocol
      28. Human albumin infusion for treating oedema in people with nephrotic syndromeProtocol
      29. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney diseaseProtocol
      30. Interventions for chronic non-hypovolaemic hypotonic hyponatraemiaProtocol
      31. Interventions for improving health literacy in people with chronic kidney diseaseProtocol
      32. Interventions for increasing solid organ donor registrationProtocol
      33. Interventions for infected cysts in people with autosomal dominant polycystic kidney diseaseProtocol
      34. Interventions for itch in people with advanced chronic kidney diseaseProtocol
      35. Interventions for post-transplant anaemia in kidney transplant recipientsProtocol
      36. Interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapyProtocolWithdrawn
      37. Interventions for preventing thrombosis in solid organ transplant recipientsProtocol
      38. Interventions for promoting adherence to fluid intake and dietary salt restriction in people with end-stage kidney diseaseProtocol
      39. Interventions for treating central venous haemodialysis catheter malfunctionProtocol
      40. Interventions for treating urinary stones in childrenProtocol
      41. Interventions for undescended testes in childrenProtocol
      42. Magnesium-based interventions for people with chronic kidney diseaseProtocol
      43. Medical and dietary interventions for preventing recurrent urinary stones in childrenProtocol
      44. New oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney diseaseProtocol
      45. Normothermic and hypothermic machine perfusion preservation versus static cold storage for deceased donor kidney transplantationProtocol
      46. Omega-3 fatty acids for vascular access outcomes in patients with chronic kidney diseaseProtocol
      47. Oral iron for people with chronic kidney diseaseProtocol
      48. Peritoneal dialysis for acute kidney injuryProtocol
      49. Pharmacological interventions for heart failure in people with chronic kidney diseaseProtocol
      50. Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapyProtocol
      51. Pharmacological interventions for preventing contrast-induced nephropathyProtocolWithdrawn
      52. Probiotics for preventing urinary tract infection in people with neuropathic bladderProtocol
      53. Protocol biopsies following kidney transplantationProtocol
      54. Reduction of dialysate temperature for intradialytic hypotension during haemodialysisProtocolWithdrawn
      55. Renal replacement therapy for preventing contrast-induced nephropathyProtocolWithdrawn
      56. Subcutaneous versus intravenous erythropoietin for long-term dialysis patientsProtocolWithdrawn
      57. Target of rapamycin inhibitors (TORi) as maintenance immunosuppression for kidney transplant recipientsProtocolWithdrawn
      58. Timing of continuous renal replacement therapy initiation for acute kidney injuryProtocol
      59. Treatment for hepatitis C virus-associated cryoglobulinaemic vasculitisProtocol
      60. Tubeless versus standard percutaneous nephrolithotomy for treating kidney stonesProtocolWithdrawn
      61. Upper limb exercise for haemodialysis fistula surgeryProtocol
      62. Uric acid lowering therapies for preventing or delaying the progression of chronic kidney diseaseProtocol
  32. Cochrane Lung Cancer Group
  33. Cochrane Metabolic and Endocrine Disorders Group
  34. Cochrane Methodology Review Group
  35. Cochrane Movement Disorders Group
  36. Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group
  37. Cochrane Musculoskeletal Group
  38. Cochrane Neonatal Group
  39. Cochrane Neuromuscular Group
  40. Cochrane Oral Health Group
  41. Cochrane Pain, Palliative and Supportive Care Group
  42. Cochrane Pregnancy and Childbirth Group
  43. Cochrane Public Health Group
  44. Cochrane Schizophrenia Group
  45. Cochrane Skin Group
  46. Cochrane STI Group
  47. Cochrane Stroke Group
  48. Cochrane Tobacco Addiction Group
  49. Cochrane Upper GI and Pancreatic Diseases Group
  50. Cochrane Urology Group
  51. Cochrane Vascular Group
  52. Cochrane Work Group
  53. Cochrane Wounds Group

SEARCH